• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性黑色素瘤中T和B淋巴细胞值与预后的关系

Relationship between T and B lymphocyte values and prognosis in malignant melanoma.

作者信息

Bernengo M G, Capella G, Peruccio M, Zina G

出版信息

Br J Dermatol. 1978 Jun;98(6):655-62. doi: 10.1111/j.1365-2133.1978.tb03584.x.

DOI:10.1111/j.1365-2133.1978.tb03584.x
PMID:307959
Abstract

T and B lymphocyte populations were evaluated in 56 patients with malignant melanoma. Active rosettes (T-Ea) were decreased only in metastatic patients, while the total T population (T-Et) was decreased in all stages. In addition the metastatic patients presented significant decreases in IgD and IgM subpopulations. An increase in null cells was noted in metastatic patients. Regular controls over a period of 2 years showed that T-Ea levels were closely linked to the clinical picture. Patients whose values were constant remained cancer free, while a reduction heralded the appearance of clinical and/or radiological signs of metastasis.

摘要

对56例恶性黑色素瘤患者的T淋巴细胞和B淋巴细胞群体进行了评估。活性玫瑰花结(T-Ea)仅在转移性患者中减少,而总T细胞群体(T-Et)在所有阶段均减少。此外,转移性患者的IgD和IgM亚群显著减少。在转移性患者中发现无标记细胞增加。两年期间的常规对照显示,T-Ea水平与临床表现密切相关。T-Ea值保持恒定的患者无癌症,而其降低预示着转移的临床和/或放射学征象出现。

相似文献

1
Relationship between T and B lymphocyte values and prognosis in malignant melanoma.恶性黑色素瘤中T和B淋巴细胞值与预后的关系
Br J Dermatol. 1978 Jun;98(6):655-62. doi: 10.1111/j.1365-2133.1978.tb03584.x.
2
The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up.T淋巴细胞水平在恶性黑色素瘤中的预后价值。一项五年随访研究。
Cancer. 1983 Nov 15;52(10):1841-8. doi: 10.1002/1097-0142(19831115)52:10<1841::aid-cncr2820521014>3.0.co;2-n.
3
Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma.恶性黑色素瘤化疗前、化疗期间及化疗后T和B淋巴细胞亚群的变化
Int J Tissue React. 1984;6(6):505-11.
4
Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
Clin Immunol Immunopathol. 1983 Sep;28(3):311-24. doi: 10.1016/0090-1229(83)90098-3.
5
[Variations of B- and T-lymphocytes in the peripheral blood and variations of the stimulability of cyclic nucleotides in the T-lymphocytes of patients suffering from malignant melanoma (author's transl)].恶性黑色素瘤患者外周血中B淋巴细胞和T淋巴细胞的变化以及T淋巴细胞中环核苷酸刺激反应性的变化(作者译)
Dermatol Monatsschr. 1979 Sep;165(9):634-41.
6
[Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].[皮肤黑色素瘤患者区域淋巴结的T细胞和B细胞免疫评估及疾病预后]
Vopr Onkol. 1983;29(12):18-20.
7
Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.反复注射短小棒状杆菌和卡介苗治疗对免疫参数的影响:黑色素瘤患者的每周研究II。血清免疫球蛋白和淋巴细胞亚群的变化。
Clin Exp Immunol. 1979 Jun;36(3):456-64.
8
T-cell subsets in melanoma patients evaluated by anti-T-cell monoclonal antibodies.通过抗T细胞单克隆抗体评估黑色素瘤患者的T细胞亚群。
Thymus. 1983 Apr;5(3-4):223-33.
9
Immune responsiveness in patients with choroidal malignant melanoma.脉络膜恶性黑色素瘤患者的免疫反应性。
Am J Ophthalmol. 1979 Feb;87(2):215-20. doi: 10.1016/0002-9394(79)90146-6.
10
[Peripheral blood lymphocytes in melanoma].[黑色素瘤中的外周血淋巴细胞]
Vopr Onkol. 1977;23(2):53-6.

引用本文的文献

1
Cell mediated immune response in miniature Sinclair swine bearing cutaneous melanomas.携带皮肤黑色素瘤的小型辛克莱猪的细胞介导免疫反应。
Can J Comp Med. 1982 Apr;46(2):209-11.
2
Lymphocyte response to mitogens in patients with malignant melanoma.恶性黑色素瘤患者对丝裂原的淋巴细胞反应。
Arch Dermatol Res. 1979 May 4;264(3):351-5. doi: 10.1007/BF00412664.
3
The in vitro effect of a calf thymus extract on the peripheral blood lymphocytes of sixty-six melanoma patients.小牛胸腺提取物对66例黑色素瘤患者外周血淋巴细胞的体外作用。
Clin Exp Immunol. 1979 May;36(2):279-84.